Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2009, Article ID 132464, 4 pages
http://dx.doi.org/10.1155/2009/132464
Clinical Study

Serum Insulin-Like Growth Factor-1 and Nitric Oxide Levels in Parkinson's Disease

1Department of Neurology, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, Turkey
2Department of Biochemistry, Faculty of Medicine, Kahramanmaras Sutcu Imam University, 46050 Kahramanmaras, Turkey

Received 12 May 2008; Revised 19 October 2008; Accepted 5 January 2009

Academic Editor: Jan van Amsterdam

Copyright © 2009 Deniz Tuncel et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. M. Abou-Sleiman, M. M. K. Muqit, and N. W. Wood, “Expanding insights of mitochondrial dysfunction in Parkinson's disease,” Nature Reviews Neuroscience, vol. 7, no. 3, pp. 207–219, 2006. View at Publisher · View at Google Scholar · View at PubMed
  2. C. Nunes, L. Almeida, and J. Laranjinha, “Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC): implications for Parkinson's disease,” Neurochemistry International, vol. 47, no. 3, pp. 173–182, 2005. View at Publisher · View at Google Scholar · View at PubMed
  3. S. J. R. Heales, A. A. J. Lam, A. J. Duncan, and J. M. Land, “Neurodegeneration or neuroprotection: the pivotal role of astrocytes,” Neurochemical Research, vol. 29, no. 3, pp. 513–519, 2004. View at Publisher · View at Google Scholar
  4. R. Kavya, R. Saluja, S. Singh, and M. Dikshit, “Nitric oxide synthase regulation and diversity: implications in Parkinson's disease,” Nitric Oxide, vol. 15, no. 4, pp. 280–294, 2006. View at Publisher · View at Google Scholar · View at PubMed
  5. B. Brüne, “Nitric oxide: NO apoptosis or turning it ON?,” Cell Death & Differentiation, vol. 10, no. 8, pp. 864–869, 2003. View at Publisher · View at Google Scholar · View at PubMed
  6. S. Singh and M. Dikshit, “Apoptotic neuronal death in Parkinson's disease: involvement of nitric oxide,” Brain Research Reviews, vol. 54, no. 2, pp. 233–250, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. T. Pirttilä, S. Vanhatalo, U. Turpeinen, and R. Riikonen, “Cerebrospinal fluid insulin-like growth factor-1, insulin growth factor binding protein-2 or nitric oxide are not increased in MS or ALS,” Acta Neurologica Scandinavica, vol. 109, no. 5, pp. 337–341, 2004. View at Publisher · View at Google Scholar · View at PubMed
  8. S. Busiguina, A. M. Fernandez, V. Barrios et al., “Neurodegeneration is associated to changes in serum insulin-like growth factors,” Neurobiology of Disease, vol. 7, no. 6, pp. 657–665, 2000. View at Publisher · View at Google Scholar · View at PubMed
  9. J. L. Trejo, E. Carro, E. Garcia-Galloway, and I. Torres-Aleman, “Role of insulin-like growth factor I signaling in neurodegenerative diseases,” Journal of Molecular Medicine, vol. 82, no. 3, pp. 156–162, 2004. View at Publisher · View at Google Scholar · View at PubMed
  10. D. Offen, B. Shtaif, D. Hadad, A. Weizman, E. Melamed, and I. Gil-Ad, “Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease,” Neuroscience Letters, vol. 316, no. 3, pp. 129–132, 2001. View at Publisher · View at Google Scholar
  11. C. G. Goetz, W. Poewe, O. Rascol et al., “Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. The Movement Disorder Society Task Force on rating scales for Parkinson's disease,” Movement Disorders, vol. 19, no. 9, pp. 1020–1028, 2004. View at Publisher · View at Google Scholar · View at PubMed
  12. N. K. Cortas and N. W. Wakid, “Determination of inorganic nitrate in serum and urine by a kinetic cadmium-reduction method,” Clinical Chemistry, vol. 36, no. 8, pp. 1440–1443, 1990. View at Google Scholar
  13. E. B. Manukhina, S. Yu. Mashina, B. V. Smirin et al., “Role of nitric oxide in adaptation to hypoxia and adaptive defense,” Physiological Research, vol. 49, no. 1, pp. 89–97, 2000. View at Google Scholar
  14. J. R. Sanchez-Ramos, E. Overvik, and B. N. Ames, “A marker of oxyradical-mediated DNA damage. (8-hydroxy- 2deoxyguanosine) is increased in nigro striatum of Parkinson's disease brain,” Neurodegen, vol. 3, pp. 197–204, 1994. View at Google Scholar
  15. J. A. Molina, F. J. Jiménez-Jiménez, J. A. Navarro et al., “Cerebrospinal fluid nitrate levels in patients with Parkinson's disease,” Acta Neurologica Scandinavica, vol. 93, no. 2-3, pp. 123–126, 1996. View at Google Scholar
  16. R. Shukla, M. Rajani, N. Srivastava, M. K. Barthwal, and M. Dikshit, “Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease,” International Journal of Neuroscience, vol. 116, no. 12, pp. 1391–1402, 2006. View at Publisher · View at Google Scholar · View at PubMed
  17. J. Kalra, A. H. Rajput, S. V. Mantha, A. K. Chaudhary, and K. Prasad, “Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease,” Molecular and Cellular Biochemistry, vol. 112, no. 2, pp. 181–186, 1992. View at Publisher · View at Google Scholar
  18. G. A. Qureshi, S. Baig, I. Bednar, P. Sodersten, G. Forsberg, and A. Siden, “Increased cerebrospinal fluid concentration of nitrite ire Parkinson's disease,” NeuroReport, vol. 6, no. 12, pp. 1642–1644, 1995. View at Google Scholar
  19. M. A. Kuiper, J. J. Visser, P. L. M. Bergmans, P. Scheltens, and E. C. Wolters, “Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients,” Journal of the Neurological Sciences, vol. 121, no. 1, pp. 46–49, 1994. View at Publisher · View at Google Scholar
  20. J. Huskić, A. Paperniku, A. Husić, F. Alendar, and N. Mulabegović, “Significantly reduced salivary nitric oxide synthesis in patients with Parkinson's disease,” Bosnian Journal of Basic Medical Sciences, vol. 5, no. 3, pp. 86–89, 2005. View at Google Scholar
  21. E. Carro and I. Torres-Aleman, “The role of insulin and insulin-like growth factor I in the molecular and cellular mechanisms underlying the pathology of Alzheimer's disease,” European Journal of Pharmacology, vol. 490, no. 1–3, pp. 127–133, 2004. View at Publisher · View at Google Scholar · View at PubMed
  22. J. Guan, R. Krishnamurthi, H. J. Waldvogel, R. L. M. Faull, R. Clark, and P. Gluckman, “N-terminal tripeptide of IGF-1 (GPE) prevents the loss of TH positive neurons after 6-OHDA induced nigral lesion in rats,” Brain Research, vol. 859, no. 2, pp. 286–292, 2000. View at Publisher · View at Google Scholar
  23. R. Krishnamurthi, S. Stott, M. Maingay et al., “N-terminal tripeptide of IGF-I improves functional deficits after 6-OHDA lesion in rats,” NeuroReport, vol. 15, no. 10, pp. 1601–1604, 2004. View at Google Scholar